IceCure Medical Ltd.(ICCM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ICCM IceCure Medical Ltd.

Market Closed 03-20 16:00:00 EDT

0.6284

-0.0006

-0.10%

盘后0.6151

-0.0133-2.12%

19:34 EDT

High0.6400	Low0.6022	Vol455.27K
Open0.6300	D1 Closing0.6290	Amplitude6.01%
Mkt Cap45.95M	Tradable Cap28.43M	Total Shares73.12M
T/O281.35K	T/O Rate1.01%	Tradable Shares45.25M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ICCM","market":"US","secType":"STK","nameCN":"IceCure Medical Ltd.","latestPrice":0.6284,"timestamp":1774036800000,"preClose":0.629,"halted":0,"volume":455271,"hourTrading":{"tag":"盘后","latestPrice":0.6151,"preClose":0.6284,"latestTime":"19:34 EDT","volume":3049,"amount":1874.2222,"timestamp":1774049660959,"change":-0.0133,"changeRate":-0.021165,"amplitude":0},"delay":0,"changeRate":-0.0009538950715422018,"floatShares":45247700,"shares":73122300,"eps":-0.239999,"marketStatus":"Market Closed","change":-0.0006,"latestTime":"03-20 16:00:00 EDT","open":0.63,"high":0.640001,"low":0.6022,"amount":281354.99677305,"amplitude":0.060097,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.239999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"listingDate":1629950400000,"exchange":"NASDAQ","adjPreClose":0.629,"preHourTrading":{"tag":"盘前","latestPrice":0.621,"preClose":0.629,"latestTime":"09:29 EDT","volume":1500,"amount":931.5,"timestamp":1774013373720,"change":-0.008,"changeRate":-0.012719,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.6151,"preClose":0.6284,"latestTime":"19:34 EDT","volume":3049,"amount":1874.2222,"timestamp":1774049660959,"change":-0.0133,"changeRate":-0.021165,"amplitude":0},"volumeRatio":0.907230793378462},"requestUrl":"/m/hq/s/ICCM","defaultTab":"news","newsList":[{"id":"2620198402","title":"Icecure Medical Rides FDA, ASBRS Wins to Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2620198402","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620198402?lang=en_us&edition=fundamental","pubTime":"2026-03-18 08:16","pubTimestamp":1773792996,"startTime":"0","endTime":"0","summary":"Icecure Medical Ltd. (($ICCM)) has held its Q4 earnings call. Read on for the main highlights of the call. Icecure Medical’s latest earnings call s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/icecure-medical-rides-fda-asbrs-wins-to-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/icecure-medical-rides-fda-asbrs-wins-to-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","BK4588","BK4082","ICCM"],"gpt_icon":0},{"id":"2620671408","title":"IceCure Medical Director Li Haixiang Resigns Effective March 17, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620671408","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620671408?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:07","pubTimestamp":1773778047,"startTime":"0","endTime":"0","summary":"IceCure said board member Li Haixiang resigned, effective March 17, 2026. The company said the resignation was not related to any disagreement over its operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL4wLV8c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2620276074","title":"IceCure Medical reports FY25 EPS 24c vs 30c last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276074","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620276074?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:49","pubTimestamp":1773751774,"startTime":"0","endTime":"0","summary":"Reports FY25 revenue $3.379M vs $3.291M last year. “2025 was a pivotal year for IceCure. Following the FDA’s clearance for cryoablation of low-risk...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/icecure-medical-reports-fy25-eps-24c-vs-30c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/icecure-medical-reports-fy25-eps-24c-vs-30c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ICCM"],"gpt_icon":0},{"id":"2620222334","title":"Israel's IceCure Medical 2025 gross margin falls to 36% on higher costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2620222334","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620222334?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:46","pubTimestamp":1773751570,"startTime":"0","endTime":"0","summary":"Israel's IceCure Medical 2025 gross margin falls to 36% on higher costsOverviewIsrael cryoablation device maker's 2025 revenue rose, driven by global sales growthGross margin for 2025 declined to 36% ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL1N4050I3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2620942287","title":"Icecure Medical Q4 EPS $(0.06) Misses $(0.04) Estimate, Sales $1.279M Miss $1.900M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942287","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620942287?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:32","pubTimestamp":1773750759,"startTime":"0","endTime":"0","summary":"Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.04) by 33.33 percent. This is a 25 percent increase over losses of $(0.08) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51293833/icecure-medical-q4-eps-0-06-misses-0-04-estimate-sales-1-279m-miss-1-900m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2620422851","title":"IceCure FY 2025 net loss narrows 5% to USD 15.06 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620422851","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620422851?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:31","pubTimestamp":1773750695,"startTime":"0","endTime":"0","summary":"IceCure published a full-year earnings press release reporting FY 2025 revenue of USD 3.38 million, up 5%. FY 2025 gross profit was USD 1.23 million and gross margin was 36%, down 8 percentage points, which the company attributed mainly to no revenue from an exclusive distribution agreement in Japan and higher cost of revenues. FY 2025 net loss was USD 15.06 million, and net loss per share was USD 0.24. Cash and cash equivalents including short-term deposits totaled USD 8.9 million at year-end. Management said U.S. adoption of its ProSense cryoablation system is being supported by FDA clearance for low-risk breast cancer, updated American Society of Breast Surgeons guidance recommending cryoablation for selected patients, and an FDA-approved post-marketing study protocol with enrollment expected to start in the second half of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL8MCqSc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2620775424","title":"Icecure Reports 2025 Full Year Financial & Operational Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620775424","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620775424?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA80STYF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2620228724","title":"Press Release: IceCure Reports 2025 Full Year Financial & Operational Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620228724","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620228724?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750600,"startTime":"0","endTime":"0","summary":"Record 4 quarter and full year sales of $1.3 million and $3.4 million, respectively. Strong commercial momentum for ProSense in the U.S. and globally following FDA clearance in low-risk breast cancer and medical society recommendations. 30 hybrid commercial-clinical sites to be added for FDA approved post-marketing study in addition to growing pipeline of potential commercial customers. IceCure Applies to Expand Regulatory Approval in Canada for ProSense Cryoablation to Include the Treatment of Low-Risk Breast Cancer. Conference call to be held today at 11:00 am Eastern Time. CAESAREA, Israel, March 17, 2026 /PRNewswire/ -- IceCure Medical Ltd.  , developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported record sales as of and for the twelve months ended December 31, 2025 as well as recent commercial and clinical updates.Three significant events are expected to drive commercial adoption of ProSense:. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","ICCM","BK4585","BK4082","BK4588","LABU","BK4022","BK4232"],"gpt_icon":0},{"id":"2619100485","title":"IceCure Medical publishes ProSense cryoablation presentation on local treatment of low-risk breast cancer with endocrine therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2619100485","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619100485?lang=en_us&edition=fundamental","pubTime":"2026-03-16 05:45","pubTimestamp":1773611110,"startTime":"0","endTime":"0","summary":"IceCure Medical publishes ProSense cryoablation presentation on local treatment of low-risk breast cancer with endocrine therapy. IceCure released a corporate presentation outlining its ProSense cryoablation system and its U.S. FDA marketing authorization for local treatment of low-risk breast cancer with endocrine therapy. The company said ProSense is the only minimally invasive cryoablation device with U.S. labeling for breast cancer and cited a total addressable market of USD 1.2 billion. IceCure reported regulatory approvals in 27 countries and said it has 64 full-time employees. It also described the ICE3 study, which enrolled 194 patients across 19 U.S. sites to evaluate cryoablation without lumpectomy. IceCure listed CEO Eyal Shamir and COO Shay Levav among its leadership team.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inf","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nNDL174slP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2619192214","title":"Icecure Medical Ltd  expected to post a loss of 4 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619192214","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619192214?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:36","pubTimestamp":1773405372,"startTime":"0","endTime":"0","summary":"Icecure Medical Ltd  expected to post a loss of4cents a share - Earnings Preview Icecure Medical Ltd ICCM.OQ ICCM.O is expected to  show a rise in quarterly revenue when it reports  results on March 1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N401161:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2618194203","title":"FDA approves IceCure’s ChoICE post-market study design for ProSense in low-risk breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618194203","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618194203?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:31","pubTimestamp":1773232298,"startTime":"0","endTime":"0","summary":"The FDA approved the study design for IceCure’s post-marketing ChoICE study evaluating ProSense cryoablation in the local treatment of low-risk breast cancer. IceCure said patient enrollment is expected to begin in the second half of 2026, with at least 80 patients targeted in the first year. The study is expected to enroll about 400 patients across 30 U.S. clinical sites within 36 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on March 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLbxxDkD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2618942732","title":"U.S. FDA Approves Icecure's Post-Marketing \"Choice\" Study for Prosense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618942732","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618942732?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:30","pubTimestamp":1773232206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ0N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2618958590","title":"IceCure Medical Ltd. to release full-year 2025 financial and operating results and host earnings call","url":"https://stock-news.laohu8.com/highlight/detail?id=2618958590","media":"Reuters","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618958590?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:31","pubTimestamp":1773145879,"startTime":"0","endTime":"0","summary":"IceCure Medical Ltd. to release full-year 2025 financial and operating results and host earnings call               IceCure will release its full-year 2025 financial and operating results before the N","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL3ZwSM7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2616635369","title":"IceCure Medical Highlights New PLOS One Data Showing ProSense Cryoablation Effective for Breast Fibroadenomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2616635369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616635369?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:18","pubTimestamp":1772461097,"startTime":"0","endTime":"0","summary":"Icecure Medical ( ($ICCM) ) just unveiled an announcement. On March 2, 2026, IceCure Medical announced that an independent, investigator-initiated ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/icecure-medical-highlights-new-plos-one-data-showing-prosense-cryoablation-effective-for-breast-fibroadenomas?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/icecure-medical-highlights-new-plos-one-data-showing-prosense-cryoablation-effective-for-breast-fibroadenomas?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2616370303","title":"Study Finds IceCure ProSense Cryoablation Safely Shrinks Breast Fibroadenomas 92.9% in One Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2616370303","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616370303?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:31","pubTimestamp":1772458266,"startTime":"0","endTime":"0","summary":"IceCure Medical Ltd. announced the publication of an independent, investigator-initiated retrospective analysis of prospectively collected data in PLOS One evaluating its ProSense cryoablation system for treating breast fibroadenomas. The study, conducted at the Premier Med Healthcare, Training, and Research Institute in Hungary, reported a median fibroadenoma volume reduction of 80.6% at about six months and 92.9% at one year after treatment, and found that sequential cryoprobe relocations maintained safety and efficacy. The results have already been published in the peer-reviewed journal.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL6zrhkm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2614859479","title":"Icecure Medical Ltd  expected to post a loss of 4 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2614859479","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614859479?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:47","pubTimestamp":1772200024,"startTime":"0","endTime":"0","summary":"Icecure Medical Ltd  expected to post a loss of4cents a share - Earnings Preview Icecure Medical Ltd ICCM.OQ ICCM.O is expected to  show a rise in quarterly revenue when it reports  results on March 3","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL8N3ZN1KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2613782769","title":"IceCure Medical Completes Five-Year Follow-Up in ICESECRET Kidney Cancer Cryoablation Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2613782769","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613782769?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:31","pubTimestamp":1771853473,"startTime":"0","endTime":"0","summary":"IceCure Medical Ltd. reported that it has completed the final five-year patient follow-up evaluations in ICESECRET, a prospective, multicenter, single-arm clinical trial of its ProSense cryoablation system for small renal masses in kidney cancer patients. The trial enrolled 114 patients  with localized tumors up to 5 cm treated under CT guidance, with follow-up assessments conducted through five years to collect CT-based local recurrence data and monitor procedure-related adverse events. IceCure said interim three-year data from 111 eligible patients had been presented previously, and that final study analysis is expected in the second quarter of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDLbHn6S7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2612400715","title":"Thomas Hospital Installs IceCure ProSense System for Breast Cancer Cryoablation","url":"https://stock-news.laohu8.com/highlight/detail?id=2612400715","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612400715?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:31","pubTimestamp":1771507877,"startTime":"0","endTime":"0","summary":"IceCure Medical Ltd. said Thomas Hospital in Fairhope, Alabama, part of the Infirmary Health network, purchased and installed the company’s ProSense cryoablation system, making it the first facility in Alabama to offer breast cancer cryoablation. The company said initial procedures are expected to begin in the coming weeks, with patient selection led by Dr. Katelin Holmes, and that the purchase was funded by the Thomas Hospital Foundation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL4Cmf8G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2610292795","title":"Icecure Medical (ICCM) Receives a Buy from Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2610292795","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610292795?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:35","pubTimestamp":1770906928,"startTime":"0","endTime":"0","summary":"In a report released today, Anthony Vendetti from Maxim Group reiterated a Buy rating on Icecure Medical, with a price target of $3.00. Vendetti co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/icecure-medical-iccm-receives-a-buy-from-maxim-group-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/icecure-medical-iccm-receives-a-buy-from-maxim-group-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2610958666","title":"IceCure Medical's ProSense System Adopted by Shero Imaging in Missouri","url":"https://stock-news.laohu8.com/highlight/detail?id=2610958666","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610958666?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:33","pubTimestamp":1770816811,"startTime":"0","endTime":"0","summary":"IceCure Medical Ltd. announced that Shero Imaging in St. Louis, Missouri, has purchased and installed the ProSense system, becoming the first clinic in the state to offer breast cancer cryoablation procedures with this technology. The ProSense system recently received FDA marketing authorization for the treatment of low-risk breast cancer. Shero Imaging will provide the minimally invasive procedure under the direction of Dr. Tish Singer, the clinic's founder and board-certified breast radiologist.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL3JVjw9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ICCM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.icecure-medical.com","stockEarnings":[{"period":"1week","weight":-0.0893},{"period":"1month","weight":0.0829},{"period":"3month","weight":-0.0689},{"period":"6month","weight":-0.4015},{"period":"1year","weight":-0.4973},{"period":"ytd","weight":0.03}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.006729},{"month":2,"riseRate":0.4,"avgChangeRate":-0.024554},{"month":3,"riseRate":0.6,"avgChangeRate":-0.022902},{"month":4,"riseRate":0.5,"avgChangeRate":0.014871},{"month":5,"riseRate":0,"avgChangeRate":-0.140983},{"month":6,"riseRate":0.25,"avgChangeRate":-0.086655},{"month":7,"riseRate":0.75,"avgChangeRate":0.017122},{"month":8,"riseRate":0.25,"avgChangeRate":-0.047246},{"month":9,"riseRate":0,"avgChangeRate":-0.204904},{"month":10,"riseRate":0.4,"avgChangeRate":0.0455},{"month":11,"riseRate":0.6,"avgChangeRate":-0.016804},{"month":12,"riseRate":0.4,"avgChangeRate":0.06553}],"exchange":"NASDAQ","name":"IceCure Medical Ltd.","nameEN":"IceCure Medical Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IceCure Medical Ltd.(ICCM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IceCure Medical Ltd.(ICCM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IceCure Medical Ltd.,ICCM,IceCure Medical Ltd.股票,IceCure Medical Ltd.股票老虎,IceCure Medical Ltd.股票老虎国际,IceCure Medical Ltd.行情,IceCure Medical Ltd.股票行情,IceCure Medical Ltd.股价,IceCure Medical Ltd.股市,IceCure Medical Ltd.股票价格,IceCure Medical Ltd.股票交易,IceCure Medical Ltd.股票购买,IceCure Medical Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IceCure Medical Ltd.(ICCM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IceCure Medical Ltd.(ICCM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}